Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis

Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07536204

Enrollment

Registered

2026-04-17

Start date

2023-06-01

Completion date

2027-03-31

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Diseases, Periodontal Attachment Loss, Periodontal Diseases, Periodontal Inflammation, Periodontitis

Keywords

JAK1, JAK2, Periodontitis, Gingiva, Inflammation

Brief summary

Detailed description

The goal of this observational study is to examine JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is: Is the JAK1/2 pathway overactivated in periodontitis compared to health? A secondary outcome will be to describe the histological areas, such as epithelium or lamina propria, where the JAK1/2 pathway will be activated including the different subpopulation of cells. The protocol include one visit where the gingival biopsies are taken. Participants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1/2 pathway. All participants will receive diagnosis and treatment of the gingival condition.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults * Sistemically healthy

Exclusion criteria

* Active Maliganancy * History of radiation to the head-neck region * Chemotherapy or radiation within the last 5 years * History of hepatitis B/C or HIV infection * Autoimmune diseases * Diagnosis of diabetes * Pregnancy or lactation * More than 3 hospitalizations over the last 3 years * Use of systemic antibiotics over the last 3 months * Use of systemic corticosteroids or immunosuppressants over the last 3 months * Use of cytokine therapy over the last 3 months * Use of large doses of pre/probiotic supplements over the last 3 months * Smoke more than 10 cigarettes per day

Design outcomes

Primary

Measure	Time frame	Description
JAK1/2 pathway activation in gingival tissues	Day 1	The activation of the JAK1/2 pathway will be evaluated by the phophorilation of JAK1/2 in the gingival tissues determined by western blot. Patients will be categorizied as 0, 1, 2. 0 = no phosphorilation 1. = mild phosphorilation 2. = intense phosphorilation

Countries

Chile

Contacts

CONTACTNicolas Dutzan, DDS, PhD

ndutzan@uchile.cl+56934037995

Outcome results